A5046660721- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Epigenetics and DNA Methylation
- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Screening and Detection
- Inflammatory Biomarkers in Disease Prognosis
- Esophageal Cancer Research and Treatment
- Infectious Disease Case Reports and Treatments
- Ferroptosis and cancer prognosis
- Urinary Bladder and Prostate Research
- Renal cell carcinoma treatment
- Urinary Tract Infections Management
- Medical Imaging and Pathology Studies
- Immune responses and vaccinations
- Nanoplatforms for cancer theranostics
- Cancer Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Colorectal Cancer Surgical Treatments
- Multiple and Secondary Primary Cancers
- Radiomics and Machine Learning in Medical Imaging
- Advanced Proteomics Techniques and Applications
- Cancer, Lipids, and Metabolism
- Metastasis and carcinoma case studies
Radboud University Medical Center
2016-2025
Radboud University Nijmegen
2016-2025
University Medical Center
2019-2025
Stichting Kinderoncologie Nederland
2023
Radboud Institute for Molecular Life Sciences
2020-2022
Netherlands Comprehensive Cancer Organisation
2022
Controversy exists on whether urinary tract infection (UTI) is a risk factor for bladder cancer (UBC). Here, the association investigated using data from one of largest case-control studies worldwide.Information (i) history and age at onset regular cystitis ('regular low-UTI') (ii) number UTI treated with antibiotics ('UTI-ab') 1809 UBC patients 4370 controls was analysed. Odds ratios (ORs) 95% confidence intervals (CI) adjusted age, education, smoking, use aspirin/ibuprofen were generated,...
BCG is recommended as intravesical immunotherapy to reduce the risk of tumor recurrence in patients with non-muscle invasive bladder cancer (NMIBC). Currently, it unknown whether application induces trained immunity.The aim this research was determine immunity NMIBC patients. We conducted a prospective observational cohort study 17 scheduled for therapy and measured parameters at 9 time points before during 1-year maintenance regimen. Ex vivo cytokine production by peripheral blood...
Patients with intermediate-risk non–muscle-invasive bladder cancer (IR NMIBC) have a high risk of recurrence and need effective therapies to reduce the disease or progression. This phase 1b study (NCT02720367) assessed safety tolerability TAR-200, an intravesical drug delivery system, in participants IR NMIBC. Participants recurrent NMIBC were eligible. received either two 7-d 21-d TAR-200 dosing cycles over 4–6-wk period marker lesion/ablation design. was placed window between cystoscopy...
Hyperthermia combined with chemotherapy is not a novel cancer treatment. However, the working mechanism of this combination therapy fully understood. In current in vitro study we investigated differences cytotoxicity 4 chemotherapeutic agents at 37C or 43C.The human transitional cell carcinoma lines used were RT4, RT112, 253J and T24. Cells seeded 96-well microtiter plates. After 24 hours cells treated for 60 minutes increasing concentrations mitomycin C, epirubicin, gemcitabine EO9...